Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation

Phase 2

Terminated

• Conditions: Hematologic Malignancy
• Interventions: Drug: B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)

• Registration Number: NCT06102213
• Lead Sponsor: Prolacta Bioscience

Brief Summary

This is a Phase 2a, open-label, multicenter study to evaluate the safety and efficacy of HMO (PBCLN-010) and B. infantis (PBCLN-014) on the gut microbiome and GI domination by pathobionts in participants receiving allo-HCT.

Approximately 60 participants will be enrolled in this study, and all participants will undergo screening assessments up to 28 days before the first study drug dose (D 7). Participants meeting all the eligibility criteria based on the screening assessments will be enrolled and randomly assigned to 1 of the 3 cohorts:

* Cohort A (HMO 9.0 g and B. infantis) BID

* Cohort B (HMO 4.5 g and B. infantis) BID

* Cohort C (Control Cohort): Participants in this cohort will not receive any study drug.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-09-18
• Status Verified: 2023-10
• Study First Submitted: 2023-10-09
• Study First Submitted QC: 2023-10-20
• Study First Posted: 2023-10-26
• Primary Completion: 2024-08-12
• Study Completion: 2024-08-12
• Last Update Submitted: 2024-08-16
• Last Update Posted: 2024-08-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

1. Signed informed consent prior to initiation of any study-specific procedure or treatment.
2. Male and female participants 18 to 75 years of age at the time of informed consent.
3. Planning to receive a first allo-HCT.
4. Able to comply with protocol requirements.

Exclusion Criteria

1. Participants with prior bowel resection resulting in colostomy
2. Serious medical or psychiatric illness likely to interfere with participation in study.
3. History or presence, upon clinical evaluation, of any illness that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions.
4. Female participants who are pregnant, breastfeeding, lactating, or planning to become pregnant during the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort A: HMO 9.0 g and B. infantis	B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)	HMO will be administered at 9.0 g orally twice a day (BID), and B. infantis will be administered orally twice a day (BID) (total of 43 days of dosing).
Cohort B: HMO 4.5 g and B. infantis	B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)	HMO will be administered at 4.5 g orally BID, and B. infantis will be administered orally BID (total of 43 days of dosing).

Primary Outcome Measures

Name	Time	Method
Rate of gut engraftment of B. infantis through Day 180 among recipients of PBCLN-010 in combination with PBCLN-014 compared with standard of care (SOC) (control cohort).	Through study completion,180 days
Duration of gut engraftment of B. infantis through Day 180 among recipients of PBCLN-010 in combination with PBCLN-014 compared with standard of care (SOC) (control cohort).	Through study completion,180 days
Incidence and severity of safety and tolerability measures assessed through adverse events, serious adverse events, and adverse events of special interest per treatment group	before treatment, during treatment, or ≤ 56 days after cessation of treatment

Secondary Outcome Measures

Name	Time	Method
Measures of safety and tolerability by physical examinations examined by cohort to assess the effect of oral administration of PBCLN-010 in combination with PBCLN-014	Dosing period, 43 days
Measuring cases of acute graft versus host disease (aGvHD) to determine the cumulative incidence or rate of acute graft versus host disease (aGvHD) at D180	Through study completion,180 days
Measuring the incidence of bloodstream infections, use of anti-infective agents, frequency/length of hospitalizations stays to evaluate the incidence of the infection and other safety events among recipients of study drug compared with SOC	Through study completion,180 days
Measuring temperature ≥ 38.0°C (100.4°F) sustained over a 1-hour period concurrent with ANC < 500 cells/mm3 to determine the incidence and duration of febrile neutropenia	Day -7 through neutrophil engraftment

Trial Locations

Locations (1)

The University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States